These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 26269025)

  • 21. Clinical and prognostic implications of serum uric acid levels on IgA nephropathy: a cohort study of 348 cases with a mean 5-year follow-up.
    Cheng GY; Liu DW; Zhang N; Tang L; Zhao ZZ; Liu ZS
    Clin Nephrol; 2013 Jul; 80(1):40-6. PubMed ID: 23391320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy.
    Tanaka S; Ninomiya T; Katafuchi R; Masutani K; Nagata M; Tsuchimoto A; Hirakata H; Kitazono T; Tsuruya K
    Clin Exp Nephrol; 2016 Oct; 20(5):689-698. PubMed ID: 26564155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy.
    Cruzado JM; Poveda R; Ibernón M; Díaz M; Fulladosa X; Carrera M; Torras J; Bestard O; Navarro I; Ballarín J; Romero R; Grinyó JM
    Nephrol Dial Transplant; 2011 Nov; 26(11):3596-602. PubMed ID: 21393611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The correlation analysis between the Oxford classification of Chinese IgA nephropathy children and renal outcome - a retrospective cohort study.
    Wu H; Xia Z; Gao C; Zhang P; Yang X; Wang R; Wang M; Peng Y
    BMC Nephrol; 2020 Jul; 21(1):247. PubMed ID: 32611399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary IgA nephropathy in elderly patients.
    Cheungpasitporn W; Nasr SH; Thongprayoon C; Mao MA; Qian Q
    Nephrology (Carlton); 2015 Jun; 20(6):419-25. PubMed ID: 25726845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy.
    Shima Y; Nakanishi K; Kamei K; Togawa H; Nozu K; Tanaka R; Sasaki S; Iijima K; Yoshikawa N
    Nephrol Dial Transplant; 2011 Jan; 26(1):163-9. PubMed ID: 20601366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and histopathologic profile of patients with primary IgA nephropathy seen in a tertiary hospital in India.
    Bagchi S; Singh G; Yadav R; Kalaivani M; Mahajan S; Bhowmik D; Dinda A; Agarwal SK
    Ren Fail; 2016; 38(3):431-6. PubMed ID: 26837482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of IgA nephropathy.
    Pozzi C
    J Nephrol; 2016 Feb; 29(1):21-5. PubMed ID: 26577268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progression of renal allograft histology after renal transplantation in recurrent and nonrecurrent immunoglobulin A nephropathy.
    Jeong HJ; Park SK; Cho YM; Kim MS; Kim YS; Choi J; Kim SI; Lim BJ
    Hum Pathol; 2008 Oct; 39(10):1511-8. PubMed ID: 18620732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Effects of the Serum IgA/C3 Ratio and Glomerular C3 Staining on the Renal Outcome in Adult Immunoglobulin A Nephropathy.
    Yang D; Pei G; Wang S; Qin A; Tang Y; Qin W
    Kidney Blood Press Res; 2024; 49(1):246-257. PubMed ID: 38382485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults.
    ; Coppo R; Troyanov S; Camilla R; Hogg RJ; Cattran DC; Cook HT; Feehally J; Roberts IS; Amore A; Alpers CE; Barratt J; Berthoux F; Bonsib S; Bruijn JA; D'Agati V; D'Amico G; Emancipator SN; Emma F; Ferrario F; Fervenza FC; Florquin S; Fogo AB; Geddes CC; Groene HJ; Haas M; Herzenberg AM; Hill PA; Hsu SI; Jennette JC; Joh K; Julian BA; Kawamura T; Lai FM; Li LS; Li PK; Liu ZH; Mezzano S; Schena FP; Tomino Y; Walker PD; Wang H; Weening JJ; Yoshikawa N; Zhang H
    Kidney Int; 2010 May; 77(10):921-7. PubMed ID: 20200498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
    Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
    Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mesangial C4d deposition: a new prognostic factor in IgA nephropathy.
    Espinosa M; Ortega R; Gómez-Carrasco JM; López-Rubio F; López-Andreu M; López-Oliva MO; Aljama P
    Nephrol Dial Transplant; 2009 Mar; 24(3):886-91. PubMed ID: 18842673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy.
    Maeda I; Hayashi T; Sato KK; Shibata MO; Hamada M; Kishida M; Kitabayashi C; Morikawa T; Okada N; Okumura M; Konishi M; Konishi Y; Endo G; Imanishi M
    Nephrol Dial Transplant; 2012 Jul; 27(7):2806-13. PubMed ID: 22492824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function.
    Moriyama T; Amamiya N; Ochi A; Tsuruta Y; Shimizu A; Kojima C; Itabashi M; Takei T; Uchida K; Nitta K
    Clin Exp Nephrol; 2011 Oct; 15(5):700-707. PubMed ID: 21625892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy.
    Yagi K; Okada M; Yanagida H; Kuwajima H; Ikeda M; Sugimoto K; Takemura T
    Clin Exp Nephrol; 2003 Dec; 7(4):270-4. PubMed ID: 14712355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study.
    Manno C; Strippoli GF; D'Altri C; Torres D; Rossini M; Schena FP
    Am J Kidney Dis; 2007 Jun; 49(6):763-75. PubMed ID: 17533019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validity of the Oxford classification of IgA nephropathy in children.
    Shima Y; Nakanishi K; Hama T; Mukaiyama H; Togawa H; Hashimura Y; Kaito H; Sako M; Iijima K; Yoshikawa N
    Pediatr Nephrol; 2012 May; 27(5):783-92. PubMed ID: 22134880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C; Torres DD; Rossini M; Pesce F; Schena FP
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
    Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
    Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.